Quick Answer
Editas Medicine, Inc. reported Net Income Loss of -$160.06 million for the year ending 2025.
- Editas Medicine, Inc. showed an increase of +32.5% in Net Income Loss from 2024 to 2025.
- This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Editas Medicine, Inc.'s Net Income Loss has declined by 1,069.6%.
- Historical annual values: Fiscal year 2025: -$160.06 million | Fiscal year 2024: -$237.09 million | Fiscal year 2023: -$153.22 million | Fiscal year 2022: -$220.43 million | Fiscal year 2021: -$192.50 million | Fiscal year 2020: -$115.98 million | Fiscal year 2019: -$133.75 million | Fiscal year 2018: -$109.95 million | Fiscal year 2017: -$120.32 million | Fiscal year 2016: -$97.18 million | Fiscal year 2015: -$72.90 million | Fiscal year 2014: -$13.69 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: